The research article entitled “A comparison of efficacy and safety of potassium-competitive acid blockers and proton pump inhibitors in gastric acid-related diseases: A systematic review and meta-analysis” was compiled by dr. Daniel Martin Simadibrata, Prof. Dr. dr. Ari Farial Syam, MMB, SpPD, K-GEH, FACG, FACP, FINASIM, and Yeong Yeh Lee, MD, Ph.D., FACP, FRCP, FACG, FAMM, AGAF in English and have been visited in an indexed international journal, Journal of Gastroenterology and Hepatology, on October 26, 2022.

This research was motivated by the use of a Potassium-Competitive Acid Blocker (PCAB) as a new alternative to the use of a Proton Pump Inhibitor (PPI) for suppressing stomach acid. This study aimed to examine the effectiveness and safety of using PCAB compared to PPIs in treating gastric acid-related diseases. The research data uses the results of studies of Randomized Controlled Trials (RCTs) related to acid reflux disease, either PCAB or PPI according to the peer-reviewed inclusion criteria.

From a total of 710 studies, 19 studies with 7023 patients met the inclusion criteria were included in the final analysis. The results showed that Vonoprazan (PCAB) was superior to PPIs in eradicating Helicobacter pylori and first-line erosive esophagitis, but not superior to other gastric acid-related diseases. Likewise, with short-term safety, vonoprazan (PCAB) is relatively safer than PPIs.

Further studies are needed with larger RCT samples, different populations, more varied use of PCAB (besides vonoprazan), and long-term data on PCAB are needed to confirm the findings of PCAB as an alternative gastric acid suppressant.

To get a complete research article, please visit the following link | Download the full article